ArQule, Inc. (Nasdaq: ARQL) today announced that the following presentations of clinical data for ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, will take place at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2010 in Chicago, Illinois.
● Clinical Science Symposium - Oral presentation #LBA7502: Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The symposium will take place on Saturday, June 5, 2010 from 8:00 AM - 9:30 AM, with the presentation time scheduled to begin at 9:00 AM. Note: this is a late-breaking abstract submission, the embargo for which will be lifted on June 5, 2010.
● Poster Discussion Session - Poster #3024: A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors; poster to be presented on Sunday, June 6, 2010 from 2:00 PM - 6:00 PM (poster discussion: 5:00 P.M. - 6:00 P.M)
● General Poster Session - Poster #4137: Final results from ARQ 197-114: A phase Ib safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC); to be presented on Sunday, June 6, 2010 from 2:00 PM - 6:00 PM.
● Trials in Progress Poster Session - Poster #TPS215: ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC); to be presented on Monday, June 7, 2010, 8:00 AM - 12:00 PM.
Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder